Keros Shares Dive on Halt to Trial of Pulmonary Hypertension Treatment

Dow Jones

2024/12/12

By Denny Jacob

Keros Therapeutics' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events.

Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year.

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy.

Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 12, 2024 07:38 ET (12:38 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2490800380"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490800380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490800380?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490800380","market":"hk","top_or_hot":-1,"title":"Keros Shares Dive on Halt to Trial of Pulmonary Hypertension Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events. \n</p>\n<p>\n  Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year. \n</p>\n<p>\n  The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy. \n</p>\n<p>\n   Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2024 07:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keros Shares Dive on Halt to Trial of Pulmonary Hypertension Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeros Shares Dive on Halt to Trial of Pulmonary Hypertension Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-12 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events. \n</p>\n<p>\n  Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year. \n</p>\n<p>\n  The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy. \n</p>\n<p>\n   Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2024 07:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490800380","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490800380","pubTimestamp":1734007080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Keros Therapeutics' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events.Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year.The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy.Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KROS":"Keros Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Keros股价因肺动脉高压治疗试验停止而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Keros Therapeutics' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events. \n\n\n  Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year. \n\n\n  The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy. \n\n\n   Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 07:38 ET (12:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}